Abingdon, UK, 09 September 2020:
Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft making it one of the largest occupiers on the Park.
Evotec has had a presence in Milton Park ever since the company’s merger with Oxford Asymmetry International plc back in 2000. The latest letting for expansion space, which totals 16,823 sq ft at 90 Park Drive, has meant that it is now one of the largest occupiers at Milton Park alongside other companies such as Immunocore and Adaptimmune, which also started life at Milton Park in the old white buildings as University of Oxford spin-outs.
Christophe Muller, PhD, head of Evotec’s Milton Park site and EVP global head of business development, said: “Milton Park is an integral part of Evotec’s history and more than ever its future. The current expansion has been driven by an increased demand of our high-end drug discovery services, specifically in the areas of biological and protein sciences. The additional footprint, in bespoke facilities on Milton Park, as well as the recruitment of scientific experts, are also part of our plans to develop a fully integrated platform and centre of excellence for structure-based drug discovery in the UK.”
For the full version of Milton Park's press release, please follow this link (only available in English).